Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BioCryst Pharmaceuticals
Parts 1 and 2 are randomized, placebo-controlled, single-ascending-dose (SAD) and multiple-ascending-dose (MAD) study parts, respectively, in healthy participants. Part 3 will evaluate multiple dose administrations in participants with Netherton syndrome in an open-label design. Part 4 will evaluate multiple administrations of BCX17725 in participants with Netherton syndrome in an open-label study design over 12 weeks, with an 8-week post-treatment follow-up period.
Age
12–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or non-pregnant, non-lactating female aged 18 to 55 years, inclusive (Parts 1 and 2), 18 to 65 years, inclusive (Part 3), or 12 to 65 years, inclusive (Part 4)
Confirmed diagnosis of Netherton syndrome (Parts 3 and 4)
IGA score of ≥ 3 (Parts 3 and 4) and IASI score of ≥ 16 (Part 4)
BMI between 18 and 30 kg/m\^2, inclusive (Parts 1 and 2)
Estimated glomerular filtration rate (eGFR) of ≥ 90 mL/min/1.73 m\^2 (Parts 1 and 2) or ≥ 60 mL/min/1.73 m\^2 (Part 3)
Agree to follow the protocol contraception requirements from screening until 90 days after the last dose of study drug
In the opinion of the investigator, expected to adequately comply with all required study procedures and restrictions for the duration of the study